Armata Pharmaceuticals (FRA:TG1N) Additional Paid-In Capital : €254.81 Mil(As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Armata Pharmaceuticals Additional Paid-In Capital?

Armata Pharmaceuticals's quarterly additional paid-in capital declined from Sep. 2023 (€258.82 Mil) to Dec. 2023 (€253.45 Mil) but then increased from Dec. 2023 (€253.45 Mil) to Mar. 2024 (€254.81 Mil).

Armata Pharmaceuticals's annual additional paid-in capital increased from Dec. 2021 (€201.77 Mil) to Dec. 2022 (€260.07 Mil) but then declined from Dec. 2022 (€260.07 Mil) to Dec. 2023 (€253.45 Mil).

Armata Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Armata Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Armata Pharmaceuticals Additional Paid-In Capital Chart

Armata Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

154.81

163.06

201.77

260.07

253.45

Armata Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															258.11	255.30	258.82	253.45	254.81

Armata Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Armata Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Armata Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Armata Pharmaceuticals (FRA:TG1N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Armata Pharmaceuticals Inc (FRA:TG1N) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ARMP:USA TG1M:Germany

Address

4503 Glencoe Avenue, Marina del Rey, CA, USA, 90292

Website

https://www.armatapharma.com

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Further, the company is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Armata Pharmaceuticals (FRA:TG1N) Headlines

No Headlines